Safety and efficacy of the various thrombolytic agents

Reviews in Cardiovascular Medicine

Volumn 3, Issue SUPPL. 2, 2002, Pages

  Ouriel, Kenneth ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Hemorrhage; Peripheral arterial occlusion; Thrombolytic agents

Indexed keywords

ALTEPLASE; ANISTREPLASE; FIBRIN; FIBRINOLYTIC AGENT; FIBROLASE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROLYSE; PROUROKINASE; RECOMBINANT UROKINASE; RETEPLASE; RETEVASE; SARUPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; UNCLASSIFIED DRUG; UROKINASE;

ARTERY THROMBOSIS; BAT; BINDING AFFINITY; BLEEDING; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INACTIVATION; DRUG INDICATION; DRUG SAFETY; DRUG SPECIFICITY; FIBRINOLYTIC THERAPY; HUMAN; LUNG EMBOLISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; TISSUE PERFUSION; VEIN THROMBOSIS; CLASSIFICATION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; PERIPHERAL VASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TREATMENT OUTCOME;

FIBRINOLYTIC AGENTS; HUMANS; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS; THROMBOSIS; TREATMENT OUTCOME;

EID: 0036995282     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Milstone H. A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol. 1941;42:116.
2. Alkjaersig N, Fletcher AP, Sherry S. The mechanism of clot dissolution by plasmin. J Clin Invest. 1959;38:1086.
3. Onundarson PT, Haraldsson HM, Bergmann L, et al. Plasminogen depletion during streptokinase treatment or two-chain urokinase incubation correlates with decreased clot lysability ex vivo and in vitro. Thromb Haemost. 1993;70:998-1004.
4. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med. 1933;58:485.
5. Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations. J Clin Invest. 1949;28:173.
6. Tillett WS, Johnson AJ, McCarty WR. The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients. J Clin Invest. 1955;34:169-185.
7. Cliffton EE, Grunnet M. Investigations of intravenous plasmin (fibrinolysin) in humans. Circulation. 1956;14:919.
8. Cliffton EE. The use of plasmin in humans. Ann N Y Acad Sci. 1957;68:209-229.
9. Jostring H, Barth U, Naidu R. Changes of anti-streptokinase titer following long-term streptokinase therapy. In: Martin M, Schoop W, Hirsh J, eds. New Concepts of Streptokinase Dosimetry. Vienna: Hans Huber; 1978:110.
10. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;332:349.
11. Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature. 1981;290:505.
12. ISIS-3 Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753.
13. Macfarlane RG, Pinot JJ. Fibrinolytic activity of normal urine. Nature. 1947;159:779.
14. Sobel GW, Mohler SR, Jones NW, et al. Urokinase: an activator of plasma fibrinolysin extracted from urine. Am J Physiol. 1952;171:768-769.
15. Credo RB, Burke SE, Barker WM, et al. Recombinant urokinase (r-UK): biochemistry, pharmacology, and clinical experience. In: Sasahara AA, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker, Inc.; 1997:513-537.
16. Husain SS, Lipinski B, Gurewich V, inventors; Isolation of plasminogen activators useful as therapeutic and diagnostic agents (single-chair, high-fibrin affinity urokinase).4,381,346. 1979. Patent application.
17. Ouriel K, Kandarpa K, Schuerr DM, et al. Prourokinase vs. urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial. J Vasc Interv Radiol. 1999;10:1083-1091.
18. The GUSTO Investigators. An international randomized trial comparing four thrombolytic therapies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
19. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998;98:2805-2814.
20. The GUSTO Investigators. An angiographic study within the global randomized trial of aggressive versus standard thrombolytic strategies in patients with acute myocardial infarction. N Engl J Med. 1993;329:1615.
21. Meierhenrich R, Carlsson J, Seifried E, et al. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency. Int J Cardiol. 1998;65:57-63.
22. Reteplase angiographic phase II international dose finding studies (RAPID I). Circulation. 1995;91:2725-2732.
23. Reteplase and alteplase patency investigation during myocardial infarction (RAPID II). Circulation. 1996;94:891-898.
24. Anonymous. A comparison of reteplase with alteplase for acute myocardial infarction. The global use of strategies to open occluded coronary arteries (GUSTO III) investigators. N Engl J Med. 1997;337:1118-1123.
25. Gardell SL, Duong LT, Diehl RE. Isolation, characterization and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem. 1989;264:17947-17952.
26. Schleuning WD, Bhargava A, Donner P. Desmodus rotundus (vampire bat) plasminogen activator DSPAa1: a superior thrombolytic created by evolution. In: Sasahara AA, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker, Inc.; 1997:603-623.
27. Ahmed NK, Tennant KD, Markland FS, Lacz JP. Biochemical characteristics of fibrolase, a fibrinolytic protease from snake venom. Haemostasis. 1990;20:147-154.
28. Heymans S, Vanderschueren S, Verhaeghe R, et al. Outcome and one year follow-up of intra-arterial staphylokinase in 191 patients with peripheral arterial occlusion. Thromb Haemost. 2000;83:666-671.
29. van Breda A, Robison JC, Feldman L, et al. Local thrombolysis in the treatment of arterial graft occlusions. J Vasc Surg. 1984;1:103-112.
30. Ouriel K, Welch EL, Shortell CK, et al. Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis. J Vasc Surg. 1995;22:593-597.
31. Ouriel K, Gray BH, Clair DG, Olin JW. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol. 2000;11:295-298.
32. Meyerovitz M, Goldhaber SZ, Reagan K, et al. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology. 1990;175:75-78.
33. Anonymous. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg. 1994;220:251-266.
34. Comerota AJ. A reanalysis of the STILE data. Personal communication.
35. Swischuk JL, Fox PF, Young K, et al. Transcatheter intraarterial infusion of rt-PA for acute lower limb ischemia: results and complications. J Vasc Interv Radiol. 2001;12(4):423-430.
36. Arepally A, Hofmann LV, Kim HS, et al. Weight-based rt-PA thrombolysis protocol for acute native arterial and bypass graft occlusions. J Vasc Interv Radiol. 2002;13(1):45-50.
37. Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or peripheral arterial surgery: phase I results. J Vasc Surg. 1996;23:64-73.